Clinical role of HER-2/neu expression in colorectal cancer

Journal of B.U.ON.

Volumn 18, Issue 1, 2013, Pages 98-104

  Pappas, A ^a   Lagoudianakis, Emmanuel ^b   Seretis, C ^b   Tsiambas, E ^c   Koronakis, N ^b   Toutouzas, K ^a   Katergiannakis, V ^a   Manouras, A ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b 401 GENERAL MILITARY HOSPITAL OF ATHENS   (Greece)

^c Department of Pathology   (Greece)

Author keywords

Colorectal cancer; HER 2 neu; Immunostaining

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; ARTICLE; CANCER GRADING; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION;

EID: 84879009280     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr
2. Ponz de Leon M, Rossi G, di Gregorio C et al. Epidemiology of colorectal cancer: the 21-year experience of a specialised registry. Intern Emerg Med 2007;2:269-279.
3. Lupu R, Cardillo M., Harris L, Hijazi M, Rosenberg K. Interaction Between ERB-Receptors and Heregulin in Breast Cancer Tumor Progression and Drug Resistance. Semin Cancer Biol 1995; 6: 135-145.
4. Lee KF, Simon H, Chen H, Bates B, Hung MC, Hauser C. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 1995 23;378:394-398.
5. Pierce JH, Arnstein P, DiMarco E et al. Oncogenic potential of erbB-2 in human mammary epithelial cells. Oncogene 1991;6:1189-1194. (Pubitemid 21924207)
6. Dittmar T, Husemann A, Schewe Y et al. Induction of cancer cell migration by epidermal growth factor is initiated by specific phosphorylation of tyrosine 1248 of c-erbB-2 receptor via EGFR. FASEB J 2002;16:1823-1825.
7. Kaptain S, Tan LK, Chen B. Her-2/neu and breast cancer. Diagn Mol Pathol 2001;10:139-152. (Pubitemid 32808108)
8. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-726. (Pubitemid 34111379)
9. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-792. (Pubitemid 32222155)
10. Micke P, Hengstler JG, Ros R et al. c-erbB-2 expression in small-cell lung cancer is associated with poor prognosis. Int J Cancer 2001;92:474-479. (Pubitemid 32319418)
11. Gu K, Mes-Masson AM, Gauthier J, Saad F. Overexpression of her-2/neu in human prostate cancer and benign hyperplasia. Cancer Lett 1996;99:185-189. (Pubitemid 26034633)
12. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-712. (Pubitemid 19147683)
13. Ross JS, McKenna BJ.The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 2001;19:554-568. (Pubitemid 32619394)
14. Schuell B, Gruenberger T, Scheithauer W, Zielinski Ch, Wrba F. HER 2/neu protein expression in colorectal cancer. BMC Cancer 2006;6:123-127.
15. Nathanson DR, Culliford AT 4th, Shia J et al. HER 2/neu expression and gene amplification in colon cancer. Int J Cancer 2003;105:796-802. (Pubitemid 36706103)
16. Kavanagh DO, Chambers G, O'Grady L et al. Is overexpression of HER-2 a predictor of prognosis in colorectal cancer? BMC Cancer 2009;9:1-6.
17. Park DI, Kang MS, Oh SJ et al. HER-2/neu overexpression is an independent prognostic factor in colorectal cancer. Int J Colorectal Dis 2007;22:491-497. (Pubitemid 46488053)
18. Osako T, Miyahara M, Uchino S, Inomata M, Kitano S, Kobayashi M. Immunohistochemical study of c-erbB-2 protein in colorectal cancer and the correlation with patient survival. Oncology 1998;55:548-555. (Pubitemid 28479114)
19. Kay EW, Mulcahy H, Walsh CB, Leader M, O'Donoghue D. Cytoplasmic c-erbB-2 protein expression correlates with survival in Dukes' B colorectal carcinoma. Histopathology 1994;25:455-461. (Pubitemid 24356788)
20. Zhou Z, Wan D, Zhang C. Expression level of c-erbB-2 protein correlates with the prognosis of patients with colorectal cancer. Zhonghua Zhong Liu Za Zhi 2001;23:139-141.
21. Penault-Llorca F, Adelaide J, Houvenaeghel G, Hassoun J, Birnbaum D, Jacquemier J. Optimization of Immunohistochemical Detection of ERBB2 in Human Breast Cancer: Impact of Fixation. J Pathol 1994; 173:65-75. (Pubitemid 24182263)
22. Tsuda H. HER-2 (c-erbB-2) test update: present status and problems. Breast Cancer 2006;13:236-248.
23. Bertheau P, Cazals-Hatem D, Meignin V et al. Variability of Immunohistochemical Reactivity on Stored Paraffin Slides. J Clin Pathol 1998; 51: 370-374. (Pubitemid 28289123)
24. Cunningham MP, Essapen S, Thomas H et al. Coexpression of the IGF-IR, EGFR and HER-2 is common in colorectal cancer patients. Int J Oncol 2006;28:329-335.
25. Half E, Broaddus R, Danenberg KD, Danenberg PV, Ayers GD, Sinicrope FA. HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors. Int J Cancer 2004;108:540-548. (Pubitemid 38036654)
26. Tsongalis GJ, Ried A Jr. HER2: the neu prognostic marker for breast cancer. Crit Rev Clin Lab Sci 2001;38:167-182. (Pubitemid 32391859)
27. Lebeau A, Deimling D, Kaltz C et al. Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 2001;19:354-363. (Pubitemid 32112846)
28. Field AS, Chamberlain NL, Tran D, Morey AL. Suggestions for HER-2/neu testing in breast carcinoma, based on a comparison of immunohistochemistry and fluorescence in situ hybridisation. Pathology 2001;33:278-282. (Pubitemid 32735237)
29. Volpi EV, Bridger JM. FISH glossary: an overview of the fluorescence in situ hybridization technique. Biotechniques 2008;45:385-409.
30. Ramanathan RK, Hwang JJ, Zamboni WC et al. Low expression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumaB (Herceptin) and irinotecan therapy. A phase II trial. Cancer Invest 2004; 22:858-865. (Pubitemid 39665350)